ArticlePediatric blood & cancer2021
Combined use of emapalumab and ruxolitinib in a patient with refractory hemophagocytic lymphohistiocytosis was safe and effective.
Open access · greenAbstract readLetter
In one paragraph
Article in Pediatric blood & cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 2 pooled it
2.3field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 22 citations in OpenAlex.
- Real-world use of emapalumab in hemophagocytic lymphohistiocytosis: a scoping review of published evidence.Frontiers in pharmacology · 2026Pooled it
- HLH as an additional warning sign of inborn errors of immunity beyond familial-HLH in children: a systematic review.Frontiers in immunology · 2024Pooled it
- Clinical experience with emapalumab treatment in a group of children with primary hemophagocytic lymphohistiocytosis.Journal of human immunity · 2026Article
- Modified treatment protocol for pediatric systemic lupus erythematosus-associated hemophagocytic lymphohistiocytosis with central nervous system involvement: a case report.Frontiers in immunology · 2026Article
- Treatment strategies for relapsed/refractory hemophagocytic lymphohistiocytosis in pediatric patients.Therapeutic advances in hematology · 2026Review
- IKZF-associated inborn errors of immunity.Journal of human immunity · 2025Review
- Hemophagocytic lymphohistiocytosis: current treatment advances, emerging targeted therapy and underlying mechanisms.Journal of hematology & oncology · 2024Review
- Emapalumab as salvage therapy for adults with malignancy-associated hemophagocytic lymphohistiocytosis.Haematologica · 2024Article
- Early hematopoietic cell transplantation for familial hemophagocytic lymphohistiocytosis in a regional treatment network in Japan.International journal of hematology · 2024Article
- JAK Inhibitors in Cytokine Storm Syndromes.Advances in experimental medicine and biology · 2024Review
- Emapalumab for the treatment of refractory cytokine release syndrome in pediatric patients.Blood advances · 2023Article
- Efficacy and safety of emapalumab in macrophage activation syndrome.Annals of the rheumatic diseases · 2023Article
- Advances in attractive therapeutic approach for macrophage activation syndrome in COVID-19.Frontiers in immunology · 2023Review
- Cellular and transcriptional impacts of Janus kinase and/or IFN-gamma inhibition in a mouse model of primary hemophagocytic lymphohistiocytosis.Frontiers in immunology · 2023Article
- Case report: Optimized ruxolitinib-based therapy in an infant with familial hemophagocytic lymphohistiocytosis type 3.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 2 institutions in 1 country.
Michael P TriebwasserDivision of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.ORCID 0000-0002-4849-2812
David M BarrettDivision of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Hamid BassiriDepartment of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Nancy BuninDivision of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Caitlin ElgartenDivision of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.ORCID 0000-0002-2474-3031
Jason FreedmanDivision of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Abdallah S GeeraRenal, Electrolyte, and Hypertension Division, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Dimitri MonosDepartment of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Michele P LambertDepartment of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0000-0003-0439-402X
Timothy OlsonDivision of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Alix E SeifDivision of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.ORCID 0000-0002-1799-2582
Michele PaesslerImmune Dysregulation Frontier Program, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Whitney PetrosaImmune Dysregulation Frontier Program, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Anne F ReillyDivision of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Neil RombergDepartment of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Kathleen E SullivanDepartment of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Ghazal Z QuinnRenal, Electrolyte, and Hypertension Division, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Edward BehrensDepartment of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
David T TeacheyDivision of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.ORCID 0000-0001-7373-8987
Children's Hospital of Philadelphia · USUniversity of Pennsylvania · US
Funding
RED CELL HEMOGLOBIN RESEARCH TRAINING PROGRAMT32HL007150 · NHLBI · CHILDREN'S HOSP OF PHILADELPHIA · PI STELLA T CHOU, Mortimer Poncz · 1985 to 2026
$7.4MNew Mechanistic Insights & Therapeutic Applications of Megakaryocytes/PlateletsR35HL150698 · NHLBI · CHILDREN'S HOSP OF PHILADELPHIA · PI Mortimer Poncz · 2020 to 2026
$7.3MNHLBI NIH HHS R35 HL150698NHLBI NIH HHS T32 HL007150
Abstract
PubMed holds no abstract for this paper.
Indexed as
Lymphohistiocytosis, HemophagocyticAntibodies, MonoclonalAntibodies, NeutralizingDrug CombinationsHumansNitrilesPyrazolesPyrimidinesAntibodies, MonoclonalAntibodies, NeutralizingDrug CombinationsEmapalumabNitrilesPyrazolesPyrimidinesruxolitinib
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.